Effects of Food on the Pharmacokinetics and Safety of HA121-28 Tablet, a Novel Multi-Targeting Tyrosine Kinase Inhibitor, in Healthy Chinese Subjects: A Phase I Clinical Trial
Drug Design, Development and Therapy · 2025
DOI: 10.2147/dddt.s484310 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Drug Design, Development and Therapy, 2025. Verfasst von Yixian Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China. Hauptthemen laut MEDLINE: Food-Drug Interactions, Protein Kinase Inhibitors, Protein-Tyrosine Kinases. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.
- Clinical Trial Center, NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.
ORCID-Profile: Yixian Liu, Xiaoyu Li, Li Zheng
Zitieren
APA
Liu, Y., Li, X., Zhang, M., Men, Y., Wang, Y., Zhu, X., & Zheng, L. (2025). Effects of Food on the Pharmacokinetics and Safety of HA121-28 Tablet, a Novel Multi-Targeting Tyrosine Kinase Inhibitor, in Healthy Chinese Subjects: A Phase I Clinical Trial. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s484310
Vancouver
Liu Y, Li X, Zhang M, Men Y, Wang Y, Zhu X, et al. Effects of Food on the Pharmacokinetics and Safety of HA121-28 Tablet, a Novel Multi-Targeting Tyrosine Kinase Inhibitor, in Healthy Chinese Subjects: A Phase I Clinical Trial. Drug Design, Development and Therapy. 2025. doi:10.2147/dddt.s484310
BibTeX
@article{Liu2025,
author = {Liu, Yixian and Li, Xiaoyu and Zhang, Mengyu and Men, Yuchun and Wang, Ying and Zhu, Xiaohong and Zheng, Li},
title = {Effects of Food on the Pharmacokinetics and Safety of HA121-28 Tablet, a Novel Multi-Targeting Tyrosine Kinase Inhibitor, in Healthy Chinese Subjects: A Phase I Clinical Trial},
journal = {Drug Design, Development and Therapy},
year = {2025},
doi = {10.2147/dddt.s484310}
}
EUVIMED